News

CV6 Therapeutics Strengthens Scientific Advisory Board with Recent Appointments

17th May 2018

Belfast, U.K. – May 17, 2018 – CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of three new members to their Scientific Advisory Board. Paul Workman, PhD, Chief Executive and President of The Institute of Cancer Research (ICR), London, […]

Read More

CV6 Therapeutics Appoints Richard Milliken as Board Chairman

19th March 2018

Belfast, U.K. – March 19, 2018 – CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Richard Milliken, CA as Chairman of the Board of Directors. “We are pleased to welcome Richard as our Board Chairman, his extensive […]

Read More

CV6 Therapeutics Appoints Chris Rivera to Board

17th March 2018

Belfast, U.K. – April 19, 2018 – CV6 Therapeutics, a drug development company focused on developing novel therapeutics to enhance the effectiveness of current standard of care therapies, announced today the appointment of Chris Riviera to the Board of Directors. “We are pleased to welcome Chris to our Board. Chris brings extensive experience in the […]

Read More

New Investor CV6 Partners with QUB in Major Cancer R&D Project

24th May 2016

With support from Invest Northern Ireland, California based CV6 Therapeutics Ltd has chosen to partner with the Centre for Cancer Research and Cell Biology at Queen’s University, Belfast for a highly innovative R&D project.

Read More